(Sharecast News) - Danish pharmaceutical group Lundbeck said on Monday that it has agreed to buy Longboard Pharmaceuticals in a $2.6bn deal.
Under the terms of the agreement, Lundbeck will pay $60 per share in cash.

Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE